ebselen
Small moleculeexperimental
Ebselen, is a synthetic organoselenium molecule under preliminary investigation as a drug candidate. It belongs to the class of compounds related to benzene and its derivatives. It is being developed by the Seattle biotechnology company, Sound Pharmaceuticals, Inc. It has also been reported to target tubulin, blocking its polymerization. — Wikipedia
Clinical trial activity
15 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
12
Phase 3
3
Phase 4
0
Earliest trial started May 1, 1999 (NCT00762671)
Timeline
Indications
Studied for
- Auditory Perception · Phase 2
- Bipolar Disorder · Phase 2
- Cochlear Diseases · Phase 2
- Coronavirus · Phase 2
- Coronavirus Infections · Phase 2
- COVID-19 · Phase 2
- Depressive Disorder, Treatment-Resistant · Phase 1
- Diabetes Mellitus, Type 1 · Phase 2/Phase 3
- Diabetes Mellitus, Type 2 · Phase 2/Phase 3
- Head and Neck Neoplasms · Phase 2
- Hearing Loss · Phase 2
- Hearing Loss, Noise-Induced · Phase 2
- Lung Neoplasms · Phase 2
- Meniere Disease · Phase 3
- Neoplasms · Phase 1
- Ototoxicity · Phase 2
- Peripheral Nerve Injuries · Phase 2
- Tinnitus · Phase 2
Mechanism of action
- Unspecified targetOTHER
Antioxidant
- Unspecified targetAntioxidant
antioxidant
Chemistry & pharmacology
Loading structure…
SMILES
O=c1c2ccccc2[se]n1-c1ccccc1- Mol. weight
- 274.18 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEbselen ↗
- ChEMBLCHEMBL51085 ↗
Also known as
- 2-phenyl-1,2-benzoisoselenazol-3(2h)-one
- dr 3305
- dr-3305
- ebselen
- ebselen
- ebselen
- ebselen
- pz 51
- pz-51
- rp 60931
- spi-1005
- spi-1005
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06859788 | Phase 3 | Apr 30, 2025 | Sound Pharmaceuticals |
| NCT06340633 | Phase 2 | Jul 31, 2024 | Sound Pharmaceuticals |
| NCT05117710 | Phase 1 | Apr 22, 2021 | Medical Research Council, University of Oxford |
| NCT04677972 | Phase 3 | Jan 31, 2021 | Sound Pharmaceuticals |
| NCT04484025 | Phase 2 | Dec 31, 2020 | Sound Pharmaceuticals, Yale University |
| NCT04483973 | Phase 2 | Dec 31, 2020 | Sound Pharmaceuticals, Yale University |
| NCT03325790 | Phase 2 | Sep 28, 2017 | Sound Pharmaceuticals |
| NCT03013400 | Phase 2 | Jun 30, 2017 | Sound Pharmaceuticals, Stanley Medical Research Institute, University of Oxford |
| NCT02819856 | Phase 1/Phase 2 (Phase 2) | May 1, 2017 | Cystic Fibrosis Foundation Therapeutics, Medical University of South Carolina, Sound Pharmaceuticals |
| NCT02779192 | Phase 2 | Sep 1, 2016 | Sound Pharmaceuticals |
| NCT01451853 | Phase 2 | Aug 1, 2016 | Department of Veteran Affairs, Sound Pharmaceuticals |
| NCT02603081 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2015 | Sound Pharmaceuticals |
| NCT01444846 | Phase 2 | Sep 1, 2011 | Sound Pharmaceuticals, University of Florida |
| NCT01452607 | Phase 1 | May 1, 2006 | MDS Pharma, Sound Pharmaceuticals |
| NCT00762671 | Phase 2/Phase 3 (Phase 3) | May 1, 1999 | Harvard University |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sound Pharmaceuticals | For profit | 13 | 12 | 3 | 2006 |
| University of Oxford | Academic/Hospital | 2 | 2 | 2 | 2017 |
| Yale University | Academic/Hospital | 2 | 0 | 1 | 2020 |
| Cystic Fibrosis Foundation Therapeutics | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Department of Veteran Affairs | Government | 1 | 0 | 1 | 2016 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 1999 |
| MDS Pharma | For profit | 1 | 0 | 1 | 2006 |
| Medical Research Council | Government | 1 | 0 | 1 | 2021 |
| Medical University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Stanley Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Florida | Academic/Hospital | 1 | 0 | 1 | 2011 |
11 organizations
Page 1 / 1